Clinical Trial Update: Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating on the combination of belantamab mafodotin, pomalidomide, and dexamethasone for high-risk plasma cell myeloma; the study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)
• DEXAMETHASONE (Dexamethasone)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Emory University | Conditions: Plasma Cell Myeloma | Phase 2 | Status: RECRUITING